Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rTMS and Live Probiotic Tablets for IBS-D
NCT06960369Phase 1Recruiting
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Dec 2024
- Primary completion
- Jun 2026
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of bifidobacterium infantis CGMCC0460.1 + lactobacillus acidophilus CGMCC0460.2 + enterococcus faecalis CGMCC0460.3 + bacillus cereus CGMCC0460.4 in Irritable bowel syndrome with diarrhea (IBS-D) (4 arms), sponsored by First Affiliated Hospital of Soochow University. Primary endpoints: Frequency of defecation and Bristol Stool Form Scale score. Started Dec 2024; status: recruiting.
02
Drugs
bifidobacterium infantis CGMCC0460.1 + lactobacillus acidophilus CGMCC0460.2 + enterococcus faecalis CGMCC0460.3 + bacillus cereus CGMCC0460.4
03
Conditions
Irritable bowel syndrome with diarrhea (IBS-D)
Beyond the preview
Go deeper on NCT06960369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06960369.